Apostolos Sarivalasis

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


49 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2013 | 2012 | 2011 | 2007 |
2024
 
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.
Ghisoni E., Morotti M., Sarivalasis A., Grimm A.J., Kandalaft L., Laniti D.D., Coukos G., 2024/11. Nature reviews. Clinical oncology, 21 (11) pp. 801-817. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A4CCCAE3C462]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C., Cardoso E., Locatelli I., Zaman K., Diciolla A., Digklia A., Stravodimou A., Cristina V., Aedo-Lopez V., Dolcan A. et al., 2024. PloS one, 19 (6) pp. e0304573. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43D02C36CEB4]
2023
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Cancer de l’endomètre : entre modernité et immunothérapie [Endometrial cancer in the crossroads of modernity and immunotherapy]
Giacomuzzi Moore B., Liapi A., Dolcan A., Kakourou A., Masmoudi S., Latifyan S., Sarivalasis A., 2023/05/17. Revue medicale suisse, 19 (827) pp. 944-949. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0D5FCD171133]
 
The SERENITY study: online Mindfulness-Based Cancer Recovery (e-MBCR) program for women living with breast and gynecological cancer—protocol for a pilot effectiveness-implementation randomized trial
Gaignard Marie-Estelle, Stanic Jelena, Bodmer Alexandre, Zaman Khalil, Sarivalasis Apostolos, Labidi-Galy Intidhar, Jermann Francoise, Di Marco Mariagrazia, Ljuslin Michael, Ryser Stephan et al., 2023/04. Journal of Psychosocial Oncology Research & Practice, 5 (2).
[DOI][serval:BIB_837DAB9F23E5]
Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature.
Wetterwald L., Sarivalasis A., Liapi A., Mathevet P., Achtari C., 2023/01/31. Cancers, 15 (3) p. 890. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_27A10B3161E6]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
[DOI][Pmid][serval:BIB_944A7B3041CF]
Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.
Liapi A., Atat C., Dunet V., Sarivalasis A., 2023. SAGE open medical case reports, 11 pp. 2050313X231176401. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8E786969EDB9]
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Lofek S., Wyss T., Melero I., de Vries IJM, Harari A., Romero P., Kandalaft L.E. et al., 2023. Frontiers in immunology, 14 p. 1119371. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_93460C0AF320]
2022
Traitements intrapéritonéaux de la carcinose ovarienne : proposition d’algorithmes décisionnels [Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm]
Undurraga M., Mathevet P., Hubner M., Buchs N.C., Warlaumont M., Sarivalasis A., Diciolla A., Lang N., Koessler T., Digklia A. et al., 2022/05/18. Revue medicale suisse, 18 (782) pp. 990-996. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_521D9B8BA734]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A., Sarivalasis A., de Jonge K., Thierry A.C., Huber F., Boudousquie C., Rossier L., Orcurto A., Imbimbo M., Baumgaertner P. et al., 2021/11/18. Cancers, 13 (22) p. 5801. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A292F2251A7]
 
213 Genomic alteration of a metastatic gastric-type cervical adenocarcinoma: hints and personalized treatment options
Sarivalasis A, Bisig B, Hastir D, Lefort K, Liapi A, 2021/10. pp. A300 dans Pathology, BMJ Publishing Group Ltd.
[DOI][WoS][serval:BIB_EB50AFBF675C]
A Locally Advanced Endometrioid Adenocarcinoma Arising from Vaginal Endometriosis: Management and Review of the Literature
Costanza M., Herrera F.G., Hastir D., Mathevet P., Sarivalasis A., 2021/09/17. Reports, 4 (3) p. 29. Peer-reviewed.
[URN][DOI][WoS][serval:BIB_47314A3E8C85]
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Chiang C.L., Rovelli R., Sarivalasis A., Kandalaft L.E., 2021/09/10. Cancers, 13 (18) p. 4553. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0968A9F9CD4C]
 
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Banerjee S., Ottevanger P.B., Sarivalasis A., Le Scodan R., Montes A., Kroep J.R., Romeo Marin M., Casado Herraez A., Auvray-Kuentz M., Westermann A.M. et al., 2021/09. Annals of Oncology, 32 pp. S1308.
[DOI][WoS][serval:BIB_AA7296087B5B]
VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature.
Liapi A., Mathevet P., Herrera F.G., Hastir D., Sarivalasis A., 2021/03. Frontiers in oncology, 11 p. 641376. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F71532CFC6B]
Oncologie [2020 oncology update]
Dei Tos G., Galli Vareia I., Huber A., Wolf B., Diciolla A., Herrera Gomez R.G., Wagner D., Digklia A., Bouchaab H., Cristina V. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 201-205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_25D6152EB267]
Anti-GD1b and anti-GM1 positive, acute inflammatory demyelinating polyneuropathy associated with advanced ovarian carcinoma: A case report
Frutiger Julie, Liapi Aikaterini, Hastir Delfyne, Hottinger Andreas, Sarivalasis Apostolos, 2021. International Journal of Case Reports and Images, 12 p. 1.
[URN][DOI][serval:BIB_AD6F8ADA616F]
Cell therapies in ovarian cancer.
Sarivalasis A., Morotti M., Mulvey A., Imbimbo M., Coukos G., 2021. Therapeutic advances in medical oncology, 13 p. 17588359211008399. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10D5AD530F84]
 
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Dafni U., Martín-Lluesma S., Balint K., Tsourti Z., Vervita K., Chenal J., Coukos G., Zaman K., Sarivalasis A., Kandalaft L.E., 2021/01. European journal of cancer, 142 pp. 63-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D084831A838B]
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2021. JMIR Research Protocols, 10 (6) pp. e30090. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7657CD7990C9]
So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature.
Herrera Gómez R.G., Hastir D., Liapi A., Dolcan A., Herrera F.G., Mathevet P., Sarivalasis A., 2021. Case reports in oncology, 14 (3) pp. 1792-1798. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E2E089A99CB8]
2020
 
Survival of the fetus: cervical cancer and pregnancy, a challenging combination.
Levy L., Meuwly J.Y., Sarivalasis A., Achtari C., Mathevet P., Herrera F.G., 2020/09/05. Lancet, 396 (10252) p. 725. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_16AC5A00A805]
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/08. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D30511CA8B6D]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_66705C7E0EE3]
Paraneoplastic Cerebellar Ataxia Can Affect Prognosis in High-Grade Serous Ovarian Cancer: A Case Report.
Liapi A., Sarivalasis A., 2020. Case reports in oncology, 13 (2) pp. 1006-1012. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2EBF9B7A049D]
Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary.
Malebranche M., Sarivalasis A., Peters S., Mathevet P., Cornuz J., Bodenmann P., 2020. Journal of primary care & community health, 11 p. 2150132720957455. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5CB413D626EE]
2019
 
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_502B05978E61]
 
EP617 Second line treatment in metastatic uterine pecoma
Liapi A, Herrera Gómez RG, Bisig B, Brouland JP, Herrera F, Mathevet P, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_1F9D59473327]
 
EP648 Subungual metastasis of an endometrial carcinoma
Vernadou A, Hastir D, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_952B5F0D28A0]
 
EP753 Single centre experience with anti-PD1 therapy in gynaecologic cancers
Ozdemir B, Dromain C, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_2C77F5B23839]
 
EP974 Review of three cases of high grade serous ovarian cancer associated with cerebellar atrophy and acute inflammatory demyelinating polyneuropathy
Liapi A, Herrera Gómez RG, Sakeliades E, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_CAA07C21D1DF]
 
L‘utilité du test CA 125
Gros Louis, Boulat Olivier, Sarivalasis Apostolos, 2019/10/23. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_91776814BFA3]
Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]
Nikolopoulou A., Galli-Vareia I., Stravodimou A., Sarivalasis A., Zaman K., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1027-1031. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44ECB7C03967]
2018
 
Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.
Zurcher Jean-Philippe, Aedo Veronica, Stravodimou Athina, Sarivalasis Apostolos, Zaman Khalil, 2018/05/20. Journal of Clinical Oncology, 36 (15_suppl) pp. e13052-e13052.
[DOI][WoS][serval:BIB_899C43F0DBF7]
 
Le cancer séreux de haut gradede l’ovaire en 2018 : avancéeset controverses [High grade serous ovarian cancer 2018 : advances and controversies]
Mederos N., Wolfer A., Mathevet P., Zaher M., Sarivalasis A., 2018/05/16. Revue medicale suisse, 14 (607) pp. 1037-1041. Peer-reviewed.
[Pmid][serval:BIB_BC5B14F6A299]
2017
 
Cancer du sein de stade précoce : la désescalade thérapeutique sélective [Selective therapeutic de-escalation in early stage breast cancer]
Liapi A., Sarivalasis A., Jeanneret Sozzi W., Lelièvre L., Zaman K., 2017/05/17. Revue medicale suisse, 13 (563) pp. 1035-1038. Peer-reviewed.
[Pmid][serval:BIB_24E1E827BE9A]
 
The case of an extensive primary extramammary Paget's disease diagnosis and treatment
Sarivalasis Apostolos, Triboulet Cécile, Anchisi Sandro, 2017. International Journal of Case Reports and Images, 8 (01) p. 46.
[DOI][serval:BIB_C9F2C6F7196D]
2015
 
An image case report of a complex pirfenidone skin rash in a patient with idiopathic pulmonary fibrosis
Sarivalasis Apostolos, Papaefthymiou Olga, Egger Bernard, 2015. International Journal of Case Reports and Images, 6 (12) p. 758.
[DOI][serval:BIB_2B0D44157FA3]
2013
 
Marqueurs tumoraux: quelle utilité en pratique clinique? [Exemples of tumor markers and their clinical utility]
Sarivalasis A., Amram M.L., Dietrich P.Y., 2013/05/22. Revue medicale suisse, 9 (387) pp. 1102-1107. Peer-reviewed.
[Pmid][serval:BIB_0D10C7658ADC]
High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton
Sarivalasis A., Bodenmann P., Langenskiold E., Lutchmaya-Flick C., Daher O., Zellweger J.P., 2013. Swiss Medical Weekly, 143 (w13860) pp. 1-6.
[URN][DOI][WoS][Pmid][serval:BIB_9FB75C5AA1EE]
2012
Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County
Sarivalasis A., Zellweger J.P., Faouzi M., Daher O., Deslarzes C., Bodenmann P., 2012. BMC Infectious Diseases, 12 (1) p. 285. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0457C3D9B12E]
2011
 
Risk factors of latent tuberculosis infection among asylum-seekers recently arrived in Switzerland : A pilot study in Vaud county
Sarivalasis A., Deslarzes C., Grossenbacher M., Daher O., Bodenmann P., Faouzi M., Zellweger J.P., 2011. pp. 5S-6S dans 79e Assemblée Annuelle de la Société Suisse de Médecine Interne Générale, Swiss Medical Forum.
[serval:BIB_2BFDDE9B44C8]
2007
 
Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women.
Konidaris S., Kouskouni E.E., Panoskaltsis T., Kreatsas G., Patsouris E.S., Sarivalassis A., Nonni A., Lazaris A.C., 2007/02. Health care for women international, 28 (2) pp. 182-191. Peer-reviewed.
[DOI][Pmid][serval:BIB_9F84518875FF]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University